Follow The Filings

SGMT Sagimet Biosciences Inc-A

Health Care, filed as SAGIMET BIOSCIENCES INC-A (COM SER A), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2

  • 2 Owners
  • Max 0.3%
  • $5.1M
  • 2 new

In 2026 Q2 Palo Alto Investors and Farallon Capital Management opened positions in Sagimet Biosciences Inc-A.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors New 0.27%
  2. Farallon Capital Management New 0.01%

Who owns SGMT

Sorted by value, long equity only, as of 2026 Q2.

History
Farallon Capital Management 0.01% New 0.01% 415,000 $3.2M History
Palo Alto Investors 0.27% New 0.27% 250,000 $1.9M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by SGMT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SGMT insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $4.2M sold by 1 insider under 10b5-1 plans
  1. George Kemble Director
    Planned sale
    $3.6M 350,987 shares at $10.23 85% of stake
    Traded Aug 14 Filed Aug 17
    ↗
  2. George Kemble Director
    Planned sale
    $201K 20,206 shares at $9.95 25% of stake
    Traded Aug 11 Filed Aug 12
    ↗
  3. George Kemble Director
    Planned sale
    $141K 18,844 shares at $7.46 23% of stake
    Traded Jul 20 Filed Jul 22
    ↗
  4. George Kemble Chair
    Planned sale
    $290K 37,688 shares at $7.69 32% of stake
    Traded Nov 20, 2025 Filed Nov 21, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 6 sales to cover taxes, 5 stock grants, and 4 option exercises.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
424B3 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01 Filing Doc
10-Q Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02,5.07 Filing Doc
8-K 5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
DEF 14A Filing Doc
8-K 5.02,8.01 Filing Doc
10-K Filing Doc
8-K 2.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated about 12 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2M — —
Net income -$27.88M -$45.57M -$51.04M
Net margin * -1393.8% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $96.65M $152.77M $116.4M
Total non-current assets * $0.073M $7.48M $0.078M
Total assets $96.72M $160.26M $116.48M
Total current liabilities $5.65M $4.45M $5.1M
Total non-current liabilities * $0.00 — —
Total equity $91.06M $155.8M $111.38M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$23.77M -$42.44M -$45.65M
Cash from investing $12.58M -$61.68M $4.56M
Cash from financing $86.17M $104.82M $0.275M
Net change in cash * $74.98M $0.701M -$40.82M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Q2 2026

Period archive